Market Closed -
Euronext Paris
11:35:18 2024-05-28 am EDT
|
5-day change
|
1st Jan Change
|
2.45
EUR
|
-2.00%
|
|
-5.22%
|
-11.36%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
665.5
|
1,037
|
338.4
|
90.57
|
198.3
|
244.9
|
-
|
-
|
Enterprise Value (EV)
1 |
403.7
|
905.2
|
242.2
|
52.81
|
121.5
|
244.3
|
65.11
|
14.79
|
P/E ratio
|
-7.24
x
|
-15.4
x
|
-3.22
x
|
-0.9
x
|
-
|
-
|
-
|
-
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
32.2
x
|
15.1
x
|
5.57
x
|
3.7
x
|
23.1
x
|
15.1
x
|
3.47
x
|
1.59
x
|
EV / Revenue
|
19.5
x
|
13.2
x
|
3.99
x
|
2.16
x
|
14.2
x
|
15.1
x
|
0.92
x
|
0.1
x
|
EV / EBITDA
|
-3.87
x
|
-14.4
x
|
-2.17
x
|
-0.56
x
|
-1.65
x
|
-2.9
x
|
-0.92
x
|
-2.58
x
|
EV / FCF
|
-5.5
x
|
-8.66
x
|
-2.15
x
|
-0.63
x
|
-5.04
x
|
-3.13
x
|
-0.63
x
|
-0.14
x
|
FCF Yield
|
-18.2%
|
-11.6%
|
-46.4%
|
-159%
|
-19.8%
|
-31.9%
|
-159%
|
-712%
|
Price to Book
|
2.36
x
|
4.56
x
|
1.69
x
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
42,446
|
42,499
|
45,478
|
45,579
|
71,751
|
99,956
|
-
|
-
|
Reference price
2 |
15.68
|
24.40
|
7.440
|
1.987
|
2.764
|
2.450
|
2.450
|
2.450
|
Announcement Date
|
3/4/20
|
3/4/21
|
3/3/22
|
3/8/23
|
4/29/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
20.65
|
68.46
|
60.69
|
24.5
|
8.58
|
16.19
|
70.57
|
154.2
|
EBITDA
1 |
-104.3
|
-62.79
|
-111.4
|
-93.88
|
-73.52
|
-84.31
|
-70.75
|
-5.728
|
EBIT
1 |
-111
|
-70.94
|
-118.2
|
-104.9
|
-90.81
|
-90.84
|
-76.98
|
-9.209
|
Operating Margin
|
-537.42%
|
-103.62%
|
-194.83%
|
-428.31%
|
-1,058.44%
|
-561.05%
|
-109.07%
|
-5.97%
|
Earnings before Tax (EBT)
1 |
-103.5
|
-80.94
|
-113.2
|
-107.9
|
-100.9
|
-74.9
|
-72.63
|
-11.95
|
Net income
1 |
-91.7
|
-67.32
|
-103.3
|
-100.5
|
-94.32
|
-74.9
|
-71.15
|
-9.357
|
Net margin
|
-444.07%
|
-98.32%
|
-170.26%
|
-410.1%
|
-1,099.3%
|
-462.64%
|
-100.81%
|
-6.07%
|
EPS
|
-2.165
|
-1.586
|
-2.308
|
-2.205
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-73.36
|
-104.6
|
-112.5
|
-83.85
|
-24.1
|
-78
|
-103.6
|
-105.3
|
FCF margin
|
-355.25%
|
-152.75%
|
-185.31%
|
-342.31%
|
-280.85%
|
-481.74%
|
-146.77%
|
-68.29%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/4/20
|
3/4/21
|
3/3/22
|
3/8/23
|
4/29/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
9.376
|
12.36
|
3.68
|
2.703
|
1.968
|
16.44
|
3.234
|
1.828
|
1.531
|
1.857
|
3.171
|
3.171
|
7.065
|
5.837
|
44.89
|
EBITDA
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-22.77
|
-21.48
|
-23.96
|
-7.22
|
-
|
-
|
EBIT
1 |
-36.69
|
-27.98
|
-33.85
|
-33.31
|
-33.98
|
-7.92
|
-21.29
|
-21.61
|
-19.24
|
-27.61
|
-23.06
|
-23.72
|
-20.4
|
-22.94
|
6.453
|
Operating Margin
|
-391.32%
|
-226.32%
|
-919.81%
|
-1,232.44%
|
-1,726.29%
|
-48.19%
|
-658.36%
|
-1,182.36%
|
-1,257.36%
|
-1,486.33%
|
-727.07%
|
-748.15%
|
-288.8%
|
-392.98%
|
14.37%
|
Earnings before Tax (EBT)
1 |
-34.7
|
-25.41
|
-33.38
|
-19.02
|
-32.03
|
-26.95
|
-29.56
|
-12.41
|
-16.18
|
-39
|
-18.5
|
-18.54
|
-20.68
|
-17.19
|
12.62
|
Net income
1 |
-32.4
|
-22.62
|
-30.64
|
-18.52
|
-29.17
|
-25.38
|
-27.33
|
-9.725
|
-16.28
|
-39.01
|
-18.5
|
-18.54
|
-20.68
|
-17.19
|
12.62
|
Net margin
|
-345.55%
|
-182.95%
|
-832.75%
|
-685.24%
|
-1,481.88%
|
-154.43%
|
-845.01%
|
-532.13%
|
-1,063.38%
|
-2,100.25%
|
-583.46%
|
-584.59%
|
-292.67%
|
-294.49%
|
28.1%
|
EPS
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/4/21
|
3/3/22
|
5/12/22
|
8/4/22
|
11/3/22
|
3/8/23
|
5/4/23
|
8/3/23
|
11/6/23
|
4/29/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
262
|
132
|
96.2
|
37.8
|
76.8
|
0.57
|
180
|
230
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-73.4
|
-105
|
-112
|
-83.9
|
-24.1
|
-78
|
-104
|
-105
|
ROE (net income / shareholders' equity)
|
-28.2%
|
-27.5%
|
-45.2%
|
-62.6%
|
-92.7%
|
-12.7%
|
3.95%
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
6.630
|
5.350
|
4.400
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-1.460
|
-1.570
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
11.5
|
37.9
|
17.9
|
2.27
|
1
|
1.24
|
1.29
|
1.32
|
Capex / Sales
|
55.91%
|
55.42%
|
29.42%
|
9.26%
|
11.67%
|
7.69%
|
1.83%
|
0.85%
|
Announcement Date
|
3/4/20
|
3/4/21
|
3/3/22
|
3/8/23
|
4/29/24
|
-
|
-
|
-
|
|
1st Jan change
|
Capi.
|
---|
| -11.36% | 271M | | +54.05% | 63.85B | | -2.02% | 41.83B | | +40.01% | 40.47B | | -10.22% | 27.17B | | +13.42% | 26.52B | | -21.60% | 18.69B | | +2.89% | 12.73B | | +22.40% | 12.11B | | +27.49% | 12.07B |
Other Biotechnology & Medical Research
|